A Pivotal trial of NOX-A12 combined with immunotherapy and standard of care in second-line pancreas cancer vs. standard of care.
Latest Information Update: 02 Nov 2020
At a glance
- Drugs Olaptesed pegol (Primary) ; Antineoplastics
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors TME Pharma
- 02 Nov 2020 New trial record